Biological Information

Background Information:

p27 is a cyclin-dependent kinase inhibitor (CKI) belonging to the Cip/Kip family, which includes p21 and p57. It binds to and inhibits CDK2-Cyclin A/E complexes, thereby preventing phosphorylation of key substrates required for the G?/S cell-cycle transition. Through this mechanism, p27 acts as a tumour suppressor, maintaining proper cell-cycle checkpoints and restricting uncontrolled proliferation. Decreased levels of p27, mainly due to proteasomal degradation, are found in various epithelial tumors originating from lung, breast, colon, ovary, esophagus, thyroid and prostate.

Target Class:

Ubiquitination-related

Family:

CDI

Sub Family:

CDKI

Protein Name:

p27

Protein Aliases:

CDKN1B; KIP1; p27Kip1 (p27)

Accession Number:

BC001971.1 (p27), NM_001798.3 (CDK2), NM_001238.1 Cyclin E1

UniProt Number:

P46527 (p27)

Gene Name:

CDKN1B (p27)

Gene ID:

1027 (p27)

Gene Aliases:

KIP1; MEN4; CDKN4; MEN1B; P27KIP1 (p27)

Target Species:

Human

Usage

Product Type:

Enzymes

Application:

Drug Discovery & Development

Storage Conditions:

1 year at -70°C

Usage disclaimer:

These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information

Assay Type:

Enzymatic

Assay Measures:

ECL

Bioassay Data

Trademark Statement:

For Research Use Only

Clinical Relevance

Therapeutic Area:

Oncology